“KT-621, an Oral, Once Daily, Targeted STAT6 Degrader: First-in-Human Phase 1a Safety, Pharmacokinetics, Pharmacodynamics and Th2 Biomarker Effects”. SKIN The Journal of Cutaneous Medicine, vol. 9, no. 6, Nov. 2025, p. s712, https://doi.org/10.25251/t4cqj323.